UC San Diego Health Sciences schools, institutes and centers are at the forefront of discovery and transformation.
A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.
UC San Diego was awarded five COVID-19 Rapid Acceleration of Diagnostics (RADx) projects by the National Institutes of Health totaling nearly $33 million, which will fund efforts that range from managing a large data center to expanding testing in disadvantaged communities.
UC San Diego School of Medicine researchers are using stem cell-derived organoids to study how SARS-CoV-2 interacts with various organ systems. Their findings may help explain the wide variety in COVID-19 symptoms and aid the search for therapies.
Research from Herbert Wertheim School of Public Health and Human Longevity Science at UC San Diego suggests that light-intensity physical activity, including shopping or a casual walk, may protect against mobility disability in older women.
Scientists at University of California San Diego School of Medicine validated a more inclusive and comprehensive genetic tool, known as a polygenic hazard score (PHS), for predicting age of onset of aggressive prostate cancer.
Researchers at UC San Diego School of Medicine use bacteriotherapy to improve symptoms of atopic dermatitis.
Forbes, May 29
San Diego Union Tribune, May 28
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
